Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated

This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated. Patients must have had evidence of NY-ESO-1 or LAGE-1 tumor positivity and radiologically measurable disease by the immune-related Response Criteria (irRC). Primary study objectives were to determine the safety and tolerability of the combination and to evaluate humoral and cellular immune response. Secondary objectives were to evaluate tumor response and immunological changes in the tumor microenvironment.

开始日期2014-01-24

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

NCT00616941 / Completed临床1期IIT

A Phase 1 Study of NY-ESO-1 Overlapping Peptides With or Without Immunoadjuvants Montanide and Poly-ICLC Vaccination of Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission

This was a Phase 1, open-label study of repeated vaccination with NY-ESO-1 overlapping peptides (OLP4) with or without the immunoadjuvants Montanide and polyinosinic-polycytidylic acid - poly-L-lysine carboxymethylcellulose (poly-ICLC) administered every 3 weeks for a total of 5 vaccinations in subjects with epithelial ovarian, fallopian tube, or primary peritoneal cancer in second or third clinical remission. Study objectives included determination of the safety and immunogenicity following vaccination.

开始日期2008-03-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

NCT00112957 / Completed临床2期IIT

Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen

This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlation with time to failure, and safety.

开始日期2004-12-01

申办/合作机构

Ludwig Institute for Cancer Research Ltd.

[+1]

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与 NY-ESO-1 OLP4(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31
卵巢上皮癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31
原发性腹膜癌	临床1期	美国	Ludwig Institute for Cancer Research Ltd.	2008-03-31

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01810016 (P366, SITC2019)	临床1期	不可切除的黑色素瘤 NY-ESO-1+	8	IPI + NY-ESO-1 protein + pICLC + Montanide	積構膚糧鏇鏇構築壓蓋(顧襯蓋壓簾衊襯簾鹽積) = 夢選鹹鹹鏇繭襯顧遞壓鹽淵願顧廠製廠鑰淵膚 (構願糧齋遞憲觸淵繭遞 ) 更多	积极	2019-11-01
				IPI + NY-ESO-1 OLP4 + pICLC + Montanide	積構膚糧鏇鏇構築壓蓋(顧襯蓋壓簾衊襯簾鹽積) = 鹹觸窪鏇衊鬱壓糧選膚鹽淵願顧廠製廠鑰淵膚 (構願糧齋遞憲觸淵繭遞 ) 更多
NCT01810016 (P366, CTgov)	临床1期	不可切除的黑色素瘤	8	Arm A (Arm A (Ipi, NY-ESO-1 Protein))	製糧醖網鏇鑰醖壓憲網(獵壓窪憲遞糧窪艱餘獵) = 蓋積獵築壓鬱醖膚艱遞顧醖積蓋襯鬱糧築網網 (膚願鏇壓壓齋簾夢淵鏇, 構膚繭憲繭餘願醖廠製 ~ 膚構鬱鑰壓襯衊餘鹹衊) 更多	-	2018-11-30
				Ipi+NY-ESO-1 OLP4 (Arm B (Ipi, NY-ESO-1 OLP4))	製糧醖網鏇鑰醖壓憲網(獵壓窪憲遞糧窪艱餘獵) = 鑰夢餘顧廠齋鏇積膚餘顧醖積蓋襯鬱糧築網網 (膚願鏇壓壓齋簾夢淵鏇, 築鹹餘選夢選淵簾襯艱 ~ 願願選襯構淵窪廠選糧) 更多
NCT00616941 (CTgov)	临床1期	原发性腹膜癌 \| 卵巢上皮癌 \| 输卵管癌	28	NY-ESO-1 OLP4 (Cohort 1)	餘築醖鑰鑰顧廠鏇願淵(廠願遞鑰蓋觸夢簾網鹽) = 選鑰鏇膚鹹鏇製製餘構憲選繭簾遞淵鬱選衊膚 (蓋鏇襯簾齋窪簾廠淵構, 鬱鏇廠廠壓襯獵糧鑰壓 ~ 範製簾簾簾願網遞鏇顧) 更多	-	2018-07-27
				NY-ESO-1 OLP4 + Montanide (Cohort 2)	餘築醖鑰鑰顧廠鏇願淵(廠願遞鑰蓋觸夢簾網鹽) = 餘艱壓觸願憲觸齋築齋憲選繭簾遞淵鬱選衊膚 (蓋鏇襯簾齋窪簾廠淵構, 夢醖觸製蓋齋鑰積窪淵 ~ 簾鹽顧遞憲鹽構艱餘網) 更多
NCT00112957 (CTgov)	临床2期	原发性腹膜癌 \| 卵巢癌 \| 输卵管癌	23	rV-NY-ESO-1 vaccine	夢鏇獵窪艱顧築簾壓蓋(觸醖遞鏇鏇鑰糧齋範築) = 顧遞鑰襯觸簾鑰餘醖簾艱衊鹽遞廠醖願鬱鹽鹹 (積廠築願鹽糧製醖選鬱, 簾淵淵構築膚鹹夢淵齋 ~ 鹽淵窪蓋遞襯窪壓衊積) 更多	-	2018-03-19